AstraZeneca, GB0009895292

AstraZeneca stock: Imfinzi wins US approval in bladder cancer treatment

Published on 11/21/2026 at 11:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock is in focus after the FDA approved a new Imfinzi regimen for muscle-invasive bladder cancer. The decision expands its oncology reach.

Regulatory progress strengthens oncology portfolio

  • The US approval covers adults with muscle-invasive bladder cancer who cannot receive or have declined cisplatin-based chemotherapy.
  • The regimen combines neoadjuvant enfortumab vedotin with Imfinzi before surgery and Imfinzi monotherapy afterward.
  • European, Japanese and other regulatory applications based on the VOLGA trial remain under review.
AstraZeneca, GB0009895292, Illustration mit AI erstellt.

AstraZeneca received US approval on Friday, November 13, 2026, for a perioperative Imfinzi regimen in adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The company said the Food and Drug Administration decision was based on the VOLGA Phase III trial.

The regimen uses enfortumab vedotin with Imfinzi before radical cystectomy, followed by Imfinzi monotherapy after surgery. In the trial's planned interim analysis, the combination reduced the risk of disease progression, recurrence, not undergoing surgery or death by 49% versus the comparator arm. Overall survival also improved, with a 42% reduction in the risk of death.

The approval adds another bladder-cancer indication for Imfinzi and broadens AstraZeneca's position in earlier-stage oncology treatment. The company said regulatory applications based on VOLGA remain under review in the European Union, Japan and several other countries.

The AstraZeneca press release said the trial included 695 patients across 182 centers in 25 countries. Grade 3 and 4 adverse events occurred in 64% of patients receiving the Imfinzi combination and 44% of patients in the comparator arm.

AstraZeneca stock traded at 160.03 euros on Lang & Schwarz at 11:33 CET on Saturday, November 21, 2026.

AstraZeneca company facts

  • Company: AstraZeneca PLC
  • ISIN: GB0009895292
  • Lang & Schwarz quote: 160.03 euros on November 21, 2026 at 11:33 CET
  • Approval: US FDA approval for perioperative Imfinzi with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer

Broader market developments can be followed in the Current market reports.

More news and analyses on AstraZeneca stock

Disclaimer...
en | GB0009895292 | ASTRAZENECA | boerse | 70542152 | bgmi